ConductScience.org, home

Comparison · NCT00590967-sae

Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) vs Treatment Group 2 (IMRT, Brachytherapy, Cisplatin): serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) vs Treatment Group 2 (IMRT, Brachytherapy, Cisplatin): serious adverse events. Trial comparisons, record NCT00590967-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00590967-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.2440.1380.393wilson
Risk in group 20.20.08070.416wilson
Risk difference, group 1 minus group 20.0439-0.1970.235newcombe hybrid score
Risk ratio, group 1 over group 21.220.4363.41log
Odds ratio, group 1 over group 21.290.3494.77log
Number needed to harm, for one more participant with a serious adverse event on Treatment Group 1 (IMRT, Brachytherapy, Cisplatin) than on Treatment Group 2 (IMRT, Brachytherapy, Cisplatin)22.8from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Treatment Group 1 (IMRT, Brachytherapy, Cisplatin)Pelvic Lymph Nodes Only Positive on FDG PET.~IMRT External Beam radiation to the para-aortic region (45 Gy)~Pelvis intracavitary brachytherapy (6 HDR treatments)~Weekly cisplatin (40 mg/m\^2)1041EG000
Group 2Treatment Group 2 (IMRT, Brachytherapy, Cisplatin)
Para-Aortic Lymph Nodes Positive on FDG PET~IMRT (50.4 Gy to para-aortic lymph node bed with a 10.8 Gy boost to nodes)~IMRT external beam pelvic radiation therapy as appropriate for stage~Intracavitary brachytherapy (6 HDR treatments)~Weekly cisplatin (40 mg/m\^2)
420EG001

Harm

What it counts
Total, serious adverse events
Time frame

Source ClinicalTrials.gov

Trial

Title
A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy
NCT number
NCT00590967
Phases
PHASE2
Conditions
Cervical Cancer
Interventions
IMRT extended field external beam radiation therapy, Brachytherapy, Cisplatin
Lead sponsor
Washington University School of Medicine
Results first posted
2016-08-29

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00590967-sae